Bacil Pharma Limited Proposes Incorporation of Wholly-Owned Subsidiary for R&D Focus
Bacil Pharma Limited has announced plans to incorporate a wholly-owned subsidiary company dedicated to research and development activities. The proposal outlines the establishment of 'Bacil Research & Development Private Limited' as a private limited entity under the control of Bacil Pharma Limited.The move is intended to expand the company’s operational scope into specialized R&D functions, along with other related allied activities permitted by applicable laws.
The proposed subsidiary will be fully owned by Bacil Pharma Limited and structured as a private limited company. This initiative aims to support the parent company's objectives in research, allowing for focused dedication toward advanced development work.
Stock Price Movement
As of 14:47, shares of Bacil Pharma Ltd are ticking up, currently trading at ₹39.98 after gaining 2.25%. The stock navigated within an intraday range, moving between a low of ₹38.45 and a high of ₹40.20.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.